Jump to

This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.

To the Editor:

Bivard and colleagues1 describe the results of a pooled analysis of 2 phase 2 randomized controlled trials investigating the effect of intravenous tenecteplase compared with alteplase in patients with acute ischemic stroke. In the pooled study population (n=146), tenecteplase did not improve the odds of an excellent clinical outcome (modified Rankin Score 0–1) at 90 days (odds ratio, 1.77; 95% confidence interval, 0.89–3.51). However, the authors report a statistically significant improvement of 90-day clinical outcomes by tenecteplase in the subgroup of patients (n=74) with target …